Wednesday, June 17, 2015

HEALTH SPENDING IS PUSHING LOW AND MIDDLE INCOME COUNTRIES FURTHER INTO POVERTY
A World Health Organization and World Bank Group report shows that 400 million people do not have access to essential health services and 6% of people in low- and middle-income countries are tipped into or pushed further into extreme poverty because of health spending
“This report is a wakeup call: It shows that we’re a long way from achieving universal health coverage. We must expand access to health and protect the poorest from health expenses that are causing them severe financial hardship,” says Dr. Tim Evans, Senior Director of Health, Nutrition and Population at the World Bank Group.

The report, Tracking Universal Health Coverage, is the first of its kind to measure health service coverage and financial protection to assess countries’ progress towards universal health coverage.

The report looked at global access to essential health services—including family planning, antenatal care, skilled birth attendance, child immunization, antiretroviral therapy, tuberculosis treatment, and access to clean water and sanitation—in 2013, and found that at least 400 million people lacked access to at least one of these services.

“The world's most disadvantaged people are missing out on even the most basic services,” says Dr. Marie-Paule Kieny, Assistant Director-General, Health Systems and Innovation, at the World Health Organization.

“A commitment to equity is at the heart of universal health coverage. Health policies and programs should focus on providing quality health services for the poorest people, women and children, people living in rural areas and those from minority groups”.

The report also found that, across 37 countries, 6% of the population was tipped or pushed further into extreme poverty ($1.25/day) because they had to pay for health services out of their own pockets. When the study factored in a poverty measure of $2/day, 17% of people in these countries were impoverished, or further impoverished, by health expenses.

“These high levels of impoverishment, which happen when poor people have to pay out of pocket for their own emergency health care, pose a major threat to the goal of eliminating extreme poverty,” says Dr. Kaushik Basu, Senior Vice President and Chief Economist at the World Bank Group. “As we transition to a post-2015 development era, we must act on these findings, or the world’s poor risk being left behind”.

WHO and the World Bank Group recommended that countries pursuing universal health coverage should aim to achieve a minimum of 80% population coverage of essential health services, and that everyone everywhere should be protected from catastrophic and impoverishing health payments.

“As more countries make commitments to universal health coverage, one of the major challenges they face is how to track progress,” says Dr. Ties Boerma, Director of the Department of Health Statistics and Information Systems at the World Health Organization. “The report shows that it is possible to quantify universal health coverage and track progress towards its key goals, both in terms of health services and financial protection coverage”.
This is the first in a series of annual reports that WHO and the World Bank Group will produce on tracking progress towards UHC across countries.

”As the saying goes, ‘what gets measured gets done.’ With countries around the world taking steps to provide universal health coverage, the ability to identify gaps and effectively measure progress will add critical momentum to this global movement,” says Michael Myers, Managing Director at The Rockefeller Foundation. “This an important tool for countries to achieve universal health coverage and build more resilient health systems”.

The Rockefeller Foundation and the Japanese Ministry of Health supported this report, which comes six months before the second annual Universal Health Coverage Day on December 12.

Source: MercoPress

Haciendo click en cada uno de los links siguientes, 
accederán a los Contenidos de nuestros 
TALLERES DE CAPACITACIÓN IN COMPANY "A MEDIDA"
de las necesidades de su Organización,
y aplicados específicamente al Sector Salud y Farma


Curso Taller ¿Cómo INCORPORAR y APLICAR Modelos de 

Curso Taller de PLANEAMIENTO ESTRATÉGICO

Curso Taller ¿Cómo implementar 

Curso Taller ¿Cómo GERENCIAR EFICIENTEMENTE 

Curso Taller ¿Cómo GERENCIAR PROCESOS DE CAMBIO 

Curso Taller de LIDERAZGO TRANSFORMACIONAL
y TOMA DE DECISIONES 


Consultas al mail: msg.latam@gmail.com
ó al TE: +5411-3532-0510


Miguel Angel Medina Casabella, MSM, MBA, SMHS .·.
Representante de The George Washington University en Foros y Ferias de LatAm desde 2001
Representante de The George Washington University Medical Center para LatAm desde 1998
CoFundador y Miembro del Consejo Directivo, GW Alumni Association, Capítulo Argentino, desde 2009
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
TE Oficina: ( 0054) 11 - 3532 - 0510
TE Celular (local): ( 011 ) 15 - 4420 - 5103
TE Celular (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella

MANAGEMENT SOLUTIONS GROUP LatAm ©   (msg.latam@gmail.com; https://www.facebook.com/MSG.LatAm
es una Consultora Interdisciplinaria cuya Misión es proveer 
soluciones integrales, eficientes y operativas en todas las áreas vinculadas a:

Estrategias Multiculturales y Transculturales, 
Management Estratégico, 
Gestión del Cambio, 
Marketing Estratégico, 
Inversiones, 
Gestión Educativa, 
Capacitación 

de Latino América (LatAm), para los Sectores:

a) Salud, Farma y Biotech,
b) Industria y Servicios,
c) Universidades y Centros de Capacitación,
d) Gobierno y ONGs.

Thursday, June 11, 2015

ALEXION TO BUY SINAGEVA BIOPHARMA IN U$S8,4 BILLIONS RARE DISEASE MEGADEAL
by Vidya L. Nathan, Natalie Grover and Bill Berkrot


Alexion Pharmaceuticals Inc said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases.

Alexion's willingness to pay an eye-popping premium for Synageva demonstrates that the appetite for large acquisitions in healthcare continues unabated. It also highlights the attraction of medicines for rare diseases that can command exceptionally high prices with little payer pushback because of the limited number of patients.

Alexion's lone product, Soliris, a treatment for two extremely rare life-threatening conditions, is among the world's most expensive drugs. The medicine, which can cost more than $500,000 per year, generated sales of $2.23 billion in 2014.

The companies' combined developmental pipelines would give Alexion eight experimental medicines in clinical trials for 11 diseases, the company said. That includes Synageva's Kanuma, which is awaiting U.S. and European approval to treat a rare and potentially fatal condition that causes a build-up of fat in the blood and liver.Alexion Chief Executive David Hallal expressed confidence that Kanuma sales will eventually exceed $1 billion.

The deal would also give Alexion Synageva's SBC-103, an experimental enzyme replacement therapy for a rare genetic disorder that has both orphan status and fast-track designation from the U.S. Food and Drug Administration. That should speed up the approval process and, in the event of approval, confer an additional seven years of marketing exclusivity, an incentive for developing medicines for small patient populations.

"I think Alexion wanted to do something big. There aren't many opportunities ... to do that, and so this is their big shot," said Paul Yook, portfolio manager at BioShares Biotechnology Funds, which holds stakes in both companies.

Yook said the announcement could put Alexion in the takeover crosshairs. "Anybody who's been looking at them now will have to make a move more quickly if they don't want to acquire Synageva as well".

MORE RAISED EYEBROWS


Alexion is offering $115 in cash and 0.6581 of its shares, or $225.92 per Synageva share, more than double its closing price of $95.87 on Tuesday.

"While some investors may be picking their jaws off the floor at such a valuation, we note that Synageva has only disclosed a fraction of its development efforts," Baird Equity Research analyst Christopher Raymond said.

Synageva's shares soared on Wednesday, ending regular trading at $203.39, up 112 percent. Alexion shares traded as low as $150.06 before finishing at $155.01, down 8 percent, a sign of investor dissatisfaction with the price the company agreed to pay for Synageva.

Paul Hudson, president of AstraZeneca's U.S. operations, speaking at the FT US Healthcare and Life Sciences Conference in New York, said he expects to see "more raised eyebrows" over future deal valuations. Whether you end up paying a high valuation is based on "whether you see some magic that others don’t see," he said.

The deal would provide a windfall for Baker Brothers Investments, which owns about 32 percent of Synageva and stands to make $2.68 billion.

There has been a steady wave of recent deals and takeover efforts in healthcare, including AbbVie's nearly $21 billion deal for Pharmacyclics and Pfizer's planned $16.7 billion purchase of Hospira.

In the rare-disease space, Teva Pharmaceutical Industries bought Auspex Pharmaceuticals for $3.5 billion, and Shire acquired NPS Pharmaceuticals for $5.2 billion. Meanwhile, Teva is pursuing generic drugmaker rival Mylan, which rejected a $43 billion offer and is itself trying to buy Ireland-based Perrigo, which in turn rebuffed Mylan's $34 billion bid.
Source: REUTERS

Haciendo click en cada uno de los links siguientes, 
accederán a los Contenidos de nuestros 
TALLERES DE CAPACITACIÓN IN COMPANY "A MEDIDA"
de las necesidades de su Organización,
y aplicados específicamente al Sector Salud y Farma


Curso Taller ¿Cómo INCORPORAR y APLICAR Modelos de 

Curso Taller de PLANEAMIENTO ESTRATÉGICO

Curso Taller ¿Cómo implementar 

Curso Taller ¿Cómo GERENCIAR EFICIENTEMENTE 

Curso Taller ¿Cómo GERENCIAR PROCESOS DE CAMBIO 

Curso Taller de LIDERAZGO TRANSFORMACIONAL
y TOMA DE DECISIONES 


Consultas al mail: msg.latam@gmail.com
ó al TE: +5411-3532-0510


Miguel Angel Medina Casabella, MSM, MBA, SMHS .·.
Representante de The George Washington University en Foros y Ferias de LatAm desde 2001
Representante de The George Washington University Medical Center para LatAm desde 1998
CoFundador y Miembro del Consejo Directivo, GW Alumni Association, Capítulo Argentino, desde 2009
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
TE Oficina: ( 0054) 11 - 3532 - 0510
TE Celular (local): ( 011 ) 15 - 4420 - 5103
TE Celular (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella

MANAGEMENT SOLUTIONS GROUP LatAm ©   (msg.latam@gmail.com; https://www.facebook.com/MSG.LatAm
es una Consultora Interdisciplinaria cuya Misión es proveer 
soluciones integrales, eficientes y operativas en todas las áreas vinculadas a:

Estrategias Multiculturales y Transculturales, 
Management Estratégico, 
Gestión del Cambio, 
Marketing Estratégico, 
Inversiones, 
Gestión Educativa, 
Capacitación 

de Latino América (LatAm), para los Sectores:

a) Salud, Farma y Biotech,
b) Industria y Servicios,
c) Universidades y Centros de Capacitación,
d) Gobierno y ONGs.